Lanoxin (Digoxin)

Digoxin works by inhibiting the Na⁺/K⁺‑ATPase pump on heart cells, leading to higher intracellular sodium. This reduces the sodium‑calcium exchange, causing calcium to accumulate inside the cells, which strengthens heart muscle contractions. It also slows conduction through the atrioventricular node, helping to regulate abnormal heart rhythms.

The dose of Lanoxin is individualized by the prescribing clinician based on factors such as the patient’s age, renal function, electrolyte status, and the severity of the cardiac condition. Blood levels of digoxin may be monitored to ensure therapeutic concentrations while minimizing toxicity.

Safety data for digoxin during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess each case carefully before prescribing.

To order Lanoxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lanoxin (digoxin) belongs to the cardiac glycoside class, offering a positive inotropic effect and AV‑node slowing, which differs from class III agents like amiodarone that primarily prolong repolarization. Digoxin is especially useful in heart failure where increased contractility is desired, whereas many other antiarrhythmics lack this inotropic benefit.

Lanoxin should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging to maintain stability, and follow aseptic techniques when preparing for intravenous administration.

Lanoxin is supplied as an injectable solution for intravenous use. It can be given as a slow bolus injection or diluted in a compatible IV fluid for infusion, according to the prescriber’s instructions and the patient’s clinical status.

The most serious risks include cardiac toxicity such as life‑threatening arrhythmias (ventricular tachycardia, fibrillation), severe bradycardia, high‑grade heart block, and hyperkalemia. Early signs of toxicity—nausea, visual changes, or confusion—should prompt immediate medical evaluation.

Lanoxin is contraindicated in patients with ventricular arrhythmias, high‑grade atrioventricular block without a pacemaker, known hypersensitivity to digoxin, and in those with uncontrolled electrolyte disturbances, particularly severe hypokalemia or hyperkalemia.